UBS analyst Ashwani Verma raised the price target on Cytokinetics (NASDAQ: CYTK) to $61.00 (from $41.00) while maintaining a Neutral ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE